Vancomycin susceptibility and clinical action: A retrospective pediatric cohort of MRSA infections with MIC equal to 2 mcg/mL

Purpose: The primary objective of this study is to examine antibiotic regimens, administered to pediatric patients with methicillin resistant Staphylococcus aureus (MRSA) infections, in comparison with current MRSA and vancomycin guidelines. Secondary objectives include examination of pharmacist interventions and the 2011 MRSA cure rate.

Methods: This is a retrospective, one year cohort study reviewing pediatric patients at Driscoll Children's Hospital (DCH) with a MRSA infection that has a vancomycin minimum inhibitory concentration (MIC) equal to 2 mcg/mL. The following inclusion criteria were met for each patient:  ≤ 18 years old at the time of infection, culture positive for MRSA, and vancomycin MIC equal to 2 mcg/mL. Patients were excluded if they did not receive at least one dose of systemic antibiotics at DCH.

Results: The study began with 191 isolates with a vancomycin MIC equal to 2 mcg/mL, which is 37% of total MRSA isolates seen at DCH in 2011. After application of the inclusion and exclusion criteria, 121 isolates remained (n=121). Data analysis is in progress and will be completed August 2012.

Conclusions: Conclusions will be available pending the completion of data analysis and will be presented at the American College of Clinical Pharmacy Annual Meeting.